Hemodez-H (Haemodes-N)

Composition Pharmacodynamics Indications Carefully Contraindications Dosing and Administration Side effects Form release / dosage
Read on
Active substancePotassium Chloride + Calcium Chloride + Magnesium Chloride + Sodium Hydrocarbonate + Sodium Chloride + Povidone-8 Thousand.Potassium Chloride + Calcium Chloride + Magnesium Chloride + Sodium Hydrocarbonate + Sodium Chloride + Povidone-8 Thousand.
Similar drugsTo uncover
  • Hemodez-8000
    solution d / infusion 
    BIOSINTEZ, PAO     Russia
  • Hemodez-H
    solution d / infusion 
    MAKSFARM, OJSC     Russia
  • Hemodez-H
    solution d / infusion 
    MOSFARM, LLC    
  • Hemodez-H
    solution d / infusion 
    ESKOM NPK, OAO     Russia
  • Hemodez-H
    solution d / infusion 
    MOSHIMFARM PREPARATES them. N.А.Semashko, OJSC     Russia
  • Hemodez-H
    solution d / infusion 
    Kursk Biofactory - BIOK, FKP     Russia
  • Hemodez-H
    solution d / infusion 
    RESTER, CJSC     Russia
  • Hemodez-H
    solution d / infusion 
    ELFARMI, LTD.     Russia
  • Hemodez-H
    solution d / infusion 
    PHARMSTANDART-UFIM VITAMIN FACTORY, OJSC     Russia
  • Hemodez-H
    solution d / infusion 
    DALHIMFARM, OJSC     Russia
  • Hemodez-H
    solution d / infusion 
    ATOLL, LLC     Russia
  • Krasgemodez 8000
    solution d / infusion 
    BIOSINTEZ, PAO     Russia
  • Krasgemodez 8000
    solution d / infusion 
    KRASFARMA, JSC     Russia
  • Neohemodes
    solution in / in 
    SYNTHESIS, OJSC     Russia
  • Neohemodes
    solution inwards 
    FIRM MEDPOLIMER, JSC     Russia
    • Dosage form: & nbspsolution for infusions
    Composition:

    1 liter of solution contains: polyvinylpyrrolidone low molecular weight medical 8000 ± 2000 - 60 g, sodium chloride - 5.5 g, potassium chloride - 0.42 g, calcium chloride 6-aqueous - 0.5 g, magnesium chloride 6-water - 0.005 g , sodium hydrogen carbonate - 0.23 g, water for injection - up to 1 liter.

    Description:Transparent liquid from light yellow to yellow.
    Pharmacotherapeutic group:Detoxifying agent
    ATX: & nbsp

    B.05.A.A   Blood plasma preparations and plasma-substituting drugs

    Pharmacodynamics:

    The action of Hemodesa-H is due to the ability low molecular weight polyvinylpyrrolidone bind toxins that circulate in the blood and quickly remove them from the body. The most fully binds toxins circulating in the blood of patients with dysentery, salmonella, food intoxication. At a burn disease at different periods of the disease, different toxins are produced. Those of them that are formed in the first 4-5 days of the disease are quite fully inactivated; toxins formed at a later date are much less neutralized.

    Toxins formed in the body of patients with acute radiation sickness do not bind, although it is possible to accelerate their excretion from the body.

    The drug contributes to the elimination of stasis of erythrocytes in capillaries, developing with intoxication of any origin, which leads to an improvement in microcirculation. It increases renal blood flow, increases glomerular filtration and increases diuresis.The drug is non-toxic, does not have antigenic and pyrogenic properties. Reducing the molecular weight of the polymer accelerates the excretion of it by the kidneys from the body and improves the detoxification properties of the preparation.

    Pharmacokinetics:
    Metabolic transformations in the body are not affected. Quickly excreted by the kidneys, within 4 hours 80% is output. and in 12-24 hours - completely.
    Indications:

    Shock (posttraumatic, postoperative, burn, hemorrhagic), intoxication (toxic diseases of the gastrointestinal tract: dysentery, dyspepsia, salmonellosis, burn, radiation and hemolytic disease, peritonitis, intestinal obstruction, thyrotoxicosis, liver disease, sepsis, pneumonia, acute phase of myocardial infarction), toxemia of newborns, gestosis.

    Contraindications:

    Hypersensitivity to the drug, intracranial hypertension, hemorrhagic stroke, condition after craniocerebral trauma, cardiovascular insufficiency IIb - III degree, respiratory failure, severe allergic reactions, thromboembolism, oliguria, anuria, acute nephritis, bronchial asthma, phlebothrombosis.

    Carefully:Not described.
    Pregnancy and lactation:Not described.
    Dosing and Administration:

    Intravenously drip (40 - 80 cap / min), through a device with a filter and a polymer needle to connect to the container.

    The dose depends on the age of the patient and the severity of intoxication.

    Single dose for adults - 200-500 ml; for children - 5-10 ml / kg; the maximum single dose for infants is 50-70 ml, 2-5 years - 100 ml, 5-10 years -150 ml, 10-15 years - 200 ml. The drug is administered once or repeatedly (up to 2 times a day) for 1-10 days, depending on the severity of intoxication. In acute gastrointestinal infections, burn and radiation diseases are administered 1-2 times a day; with hemolytic disease and toxemia of newborns - 2-8 times a day (daily or every other day); with large focal myocardial infarction (in 1 day) - 200 ml once, with complications for 2 days - 200 ml.

    Side effects:

    Reduced blood pressure, tachycardia, difficulty breathing (with rapid administration), allergic reactions of varying severity (up to the development of anaphylactic shock). Infection at the injection site, thrombosis or phlebitis, spreading from the site of infusion.

    Overdose:Not described.
    Interaction:Not described.
    Special instructions:

    With extensive burns combined with the introduction of plasma, albumin, gamma globulin.

    Before starting the infusion, the doctor must check the expiry date of the package.The drug should be clear, free of sediment, sediment and mold. Pressing the container with the preparation is checked for its tightness and the integrity of the package. The results of visual inspection are recorded in the medical history.

    During the treatment it is necessary to monitor the level of blood pressure and carefully monitor the patient's condition.

    Before administration, the solution is warmed to body temperature.
    Effect on the ability to drive transp. cf. and fur:Not described.
    Form release / dosage:

    Solution for infusions 6%.

    Packaging:250, 500 ml in polyethylene bottles for single-use infusion solutions or 250, 500 ml in polymeric containers for single-use infusion solutions. Each bottle is put in a pack of cardboard along with instructions for use. Each container is packed in a bag of polyethylene film or polyethylene-polyamide film.

    For hospitals: 24 bottles or 250 ml containers or 12 bottles or 500 ml containers, together with an equal number of instructions for use, are placed in a cardboard box.

    Storage conditions:

    In a dry place inaccessible to children, at temperatures from 0 to +20 ° C.

    Single and repeated freezing at temperatures up to -45 ° C does not affect the quality of the preparation.

    Shelf life:

    2 years. Do not use after the expiry date printed on the package.

    Terms of leave from pharmacies:On prescription
    Registration number:LS-001904
    Date of registration:11.08.2006
    Expiration Date:11.08.2011
    The owner of the registration certificate:ELFARMI, LTD. ELFARMI, LTD. Russia
    Manufacturer: & nbsp
    Information update date: & nbsp21.03.2017
    Illustrated instructions
      Instructions
      Up